ATE511400T1 - Nukleinsäure-fomulierungen zur genverabreichung - Google Patents

Nukleinsäure-fomulierungen zur genverabreichung

Info

Publication number
ATE511400T1
ATE511400T1 AT01918339T AT01918339T ATE511400T1 AT E511400 T1 ATE511400 T1 AT E511400T1 AT 01918339 T AT01918339 T AT 01918339T AT 01918339 T AT01918339 T AT 01918339T AT E511400 T1 ATE511400 T1 AT E511400T1
Authority
AT
Austria
Prior art keywords
poly
acid
nucleic acid
acid formulations
gene administration
Prior art date
Application number
AT01918339T
Other languages
English (en)
Inventor
Jason Fewell
Fiona Maclaughlin
Louis Smith
Francois Nicol
Alain Rolland
Original Assignee
Genetronics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genetronics Inc filed Critical Genetronics Inc
Application granted granted Critical
Publication of ATE511400T1 publication Critical patent/ATE511400T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1816—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plant Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Inorganic Chemistry (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
AT01918339T 2000-03-03 2001-03-02 Nukleinsäure-fomulierungen zur genverabreichung ATE511400T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US18723600P 2000-03-03 2000-03-03
US26175101P 2001-01-16 2001-01-16
PCT/US2001/006953 WO2001066149A2 (en) 2000-03-03 2001-03-02 Nucleic acid formulations for gene delivery and methods of use

Publications (1)

Publication Number Publication Date
ATE511400T1 true ATE511400T1 (de) 2011-06-15

Family

ID=26882847

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01918339T ATE511400T1 (de) 2000-03-03 2001-03-02 Nukleinsäure-fomulierungen zur genverabreichung

Country Status (9)

Country Link
US (2) US7173116B2 (de)
EP (1) EP1259265B1 (de)
JP (1) JP4987205B2 (de)
AT (1) ATE511400T1 (de)
AU (1) AU2001245427A1 (de)
BR (1) BR0108962A (de)
CA (1) CA2401327C (de)
DK (1) DK1259265T3 (de)
WO (1) WO2001066149A2 (de)

Families Citing this family (94)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040192593A1 (en) * 1999-07-26 2004-09-30 Baylor College Of Medicine Protease resistant ti-growth hormone releasing hormone
DE60023906T2 (de) * 1999-07-26 2006-07-20 Baylor College Of Medicine, Houston Superaktive, wachstumshormone freisetzende hormonanaloge vom schwein
WO2002024899A2 (en) * 2000-09-25 2002-03-28 Valentis, Inc. Improved system for regulation of transgene expression
ATE536100T1 (de) * 2001-10-26 2011-12-15 Baylor College Medicine Zusammensetzung für die änderung der knocheneigenschaften bei einem probanden
JP2005519063A (ja) * 2001-12-28 2005-06-30 スプラテック ファーマ インコーポレイティド 遺伝子の発現を向上するための多価アニオン重合体及び両親媒性ブロック共重合体を含む薬剤組成物およびその使用方法
BR0311539A (pt) * 2002-05-28 2005-10-25 Advisys Inc Liberação aumentada de um constructo de ácido nucléico in vivo pelo sistema de poli-l-glutamato ("plg")
US20080269153A1 (en) * 2002-05-28 2008-10-30 Ruxandra Draghia-Akli Increased stability of a dna formulation by including poly-l-glutamate
US20040014645A1 (en) * 2002-05-28 2004-01-22 Advisys, Inc. Increased delivery of a nucleic acid construct in vivo by the poly-L-glutamate ("PLG") system
US7316925B2 (en) 2002-07-16 2008-01-08 Vgx Pharmaceuticals, Inc. Codon optimized synthetic plasmids
AU2003302337A1 (en) * 2002-12-31 2004-07-29 The Johns Hopkins University Wound healing method and kits
WO2004067719A2 (en) * 2003-01-28 2004-08-12 Advisys, Inc. Growth hormone releasing hormone (ghrh) for use in reducing culling in herd animals
JP5171033B2 (ja) * 2003-03-11 2013-03-27 メルク セローノ ソシエテ アノニム ｍＣＭＶＩＥ２プロモーターを含んで成る発現ベクター
WO2004091495A2 (en) * 2003-04-09 2004-10-28 University Of Utah Research Foundation Compositions and methods related to production of erythropoietin
TW200424214A (en) * 2003-04-21 2004-11-16 Advisys Inc Plasmid mediated GHRH supplementation for renal failures
GB0313916D0 (en) * 2003-06-16 2003-07-23 Glaxosmithkline Biolog Sa Vaccine composition
US20090005333A1 (en) * 2004-01-26 2009-01-01 Vgx Pharmaceuticlas, Inc. Reducing culling in herd animals growth hormone releasing hormone (ghrh)
ATE549037T1 (de) 2004-09-22 2012-03-15 St Jude Childrens Res Hospital Verbesserte expression von faktor-ix in gentherapie-vektoren
TWI294460B (en) * 2004-12-23 2008-03-11 Ind Tech Res Inst Method for stabilizing nucleic acids
US20060094023A1 (en) * 2004-11-02 2006-05-04 Industrial Technology Research Institute Method for isolating nucleic acid by using amino surfactants
WO2007120234A2 (en) * 2005-12-07 2007-10-25 Genetronics, Inc Variable volume electroporation chamber and methods therefore
KR101444471B1 (ko) * 2006-03-03 2014-09-24 제네트로닉스, 인코포레이티드 외과적 절제술 이후에 조직내 남아 있는 미세 잔류 종양을 치료하는 장치
EP2548438B1 (de) 2006-11-08 2015-08-05 Veritas Bio, LLC In-vivo-Abgabe von Doppelstrang-RNA an eine Zielzelle
FR2941152B1 (fr) * 2009-01-20 2013-10-18 Centre Nat Rech Scient Vecteurs comprenant une macromolecule anionique et un lipide cationique pour l'administration de petits acides nucleiques.
WO2012018594A2 (en) * 2010-07-26 2012-02-09 Scott & White Healthcare Plant-derived polysaccharides for delivery of rna-based therapies
CA2807552A1 (en) 2010-08-06 2012-02-09 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
LT4108671T (lt) 2010-10-01 2025-01-10 Modernatx, Inc. Modifikuoti nukleozidai, nukleotidai, nukleorūgštys bei jų panaudojimas
US8710200B2 (en) 2011-03-31 2014-04-29 Moderna Therapeutics, Inc. Engineered nucleic acids encoding a modified erythropoietin and their expression
AU2012321317B2 (en) 2011-07-12 2016-01-28 Inovio Pharmaceuticals, Inc Novel clostridium difficile DNA vaccine
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
EA201490636A1 (ru) 2011-09-16 2014-08-29 Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания Сконструированные с помощью рнк t-клетки для лечения злокачественных новообразований
WO2013044225A1 (en) 2011-09-22 2013-03-28 The Trustees Of The University Of Pennsylvania A universal immune receptor expressed by t cells for the targeting of diverse and multiple antigens
SMT202200229T1 (it) 2011-10-03 2022-07-21 Modernatx Inc Nucleosidi, nucleotidi e acidi nucleici modificati e loro usi
US9272002B2 (en) 2011-10-28 2016-03-01 The Trustees Of The University Of Pennsylvania Fully human, anti-mesothelin specific chimeric immune receptor for redirected mesothelin-expressing cell targeting
RU2649364C2 (ru) 2011-12-16 2018-04-02 Модерна Терапьютикс, Инк. Составы на основе модифицированного нуклеозида, нуклеотида и нуклеиновой кислоты
CA2864688C (en) 2012-02-22 2023-09-05 The Trustees Of The University Of Pennsylvania Use of icos-based cars to enhance antitumor activity and car persistence
SG11201404284SA (en) 2012-02-22 2014-10-30 Univ Pennsylvania Use of the cd2 signaling domain in second-generation chimeric antigen receptors
US10501512B2 (en) 2012-04-02 2019-12-10 Modernatx, Inc. Modified polynucleotides
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
AU2013243954A1 (en) 2012-04-02 2014-10-30 Moderna Therapeutics, Inc. Modified polynucleotides for the production of cosmetic proteins and peptides
CN104583230A (zh) 2012-07-13 2015-04-29 宾夕法尼亚大学董事会 通过共同引入双特异性抗体增强car t细胞的活性
AR092745A1 (es) 2012-10-01 2015-04-29 Univ Pennsylvania Composiciones que comprenden un dominio de union anti-fap y metodos para hacer blanco en celulas estromales para el tratamiento del cancer
WO2014055771A1 (en) 2012-10-05 2014-04-10 The Trustees Of The University Of Pennsylvania Human alpha-folate receptor chimeric antigen receptor
US10117896B2 (en) 2012-10-05 2018-11-06 The Trustees Of The University Of Pennsylvania Use of a trans-signaling approach in chimeric antigen receptors
US9677078B2 (en) 2012-10-08 2017-06-13 Lipocalyx Gmbh Carboxylated polyamine derivatives as transfection reagents
HRP20220607T1 (hr) 2012-11-26 2022-06-24 Modernatx, Inc. Terminalno modificirana rna
US10370431B2 (en) 2013-02-15 2019-08-06 Bioverativ Therapeutics Inc. Optimized factor VIII gene
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
US10023626B2 (en) 2013-09-30 2018-07-17 Modernatx, Inc. Polynucleotides encoding immune modulating polypeptides
BR112016007255A2 (pt) 2013-10-03 2017-09-12 Moderna Therapeutics Inc polinucleotídeos que codificam receptor de lipoproteína de baixa densidade
EP3079668A1 (de) 2013-12-09 2016-10-19 Durect Corporation Pharmazeutisch aktive wirkstoffkomplexe, polymerkomplexe und zusammensetzungen und verfahren damit
ES2963718T3 (es) 2014-01-21 2024-04-01 Novartis Ag Capacidad presentadora de antígenos de células CAR-T potenciada mediante introducción conjunta de moléculas co-estimuladoras
US11008561B2 (en) 2014-06-30 2021-05-18 Bioverativ Therapeutics Inc. Optimized factor IX gene
CA2966035A1 (en) 2014-10-31 2016-05-06 The Trustees Of The University Of Pennsylvania Compositions and methods of stimulating and expanding t cells
KR102546296B1 (ko) 2014-10-31 2023-06-21 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 변형된 t 세포에서 유전자 발현의 변경 및 그의 용도
CN107106670A (zh) 2014-10-31 2017-08-29 宾夕法尼亚大学董事会 用于修饰的t细胞的方法和组合物
GB201420139D0 (en) 2014-11-12 2014-12-24 Ucl Business Plc Factor IX gene therapy
CA2975147C (en) 2015-01-31 2025-06-10 The Trustees Of The University Of Pennsylvania COMPOSITIONS AND METHODS OF ADMINISTRATION OF THERAPEUTIC MOLECULES TO T CELLS
EP4088732A1 (de) 2015-05-01 2022-11-16 The Regents of The University of California Glycan-abhängige immuntherapeutische moleküle
US11649435B2 (en) 2015-08-28 2023-05-16 The Trustees Of The University Of Pennsylvania Methods and compositions for cells expressing a chimeric intracellular signaling molecule
EP3411478B1 (de) 2016-02-01 2022-06-08 Bioverativ Therapeutics Inc. Optimierte faktor-viii-gene
EP3432924A1 (de) 2016-03-23 2019-01-30 Novartis AG Zellsekretierte minikörper und verwendungen davon
US10233419B2 (en) 2016-06-30 2019-03-19 Zymergen Inc. Apparatuses and methods for electroporation
JP2018035137A (ja) 2016-07-13 2018-03-08 マブイミューン ダイアグノスティックス エイジーＭａｂｉｍｍｕｎｅ Ｄｉａｇｎｏｓｔｉｃｓ Ａｇ 新規な抗線維芽細胞活性化タンパク質（ｆａｐ）結合薬剤およびその使用
US11827705B2 (en) 2017-03-28 2023-11-28 The Trustees Of The University Of Pennsylvania Methods to protect transplanted tissue from rejection
JP7372920B2 (ja) 2017-12-29 2023-11-01 セレクティス Ｃａｒ ｔ細胞の作製を改良するための方法
US11447769B2 (en) 2018-03-27 2022-09-20 The Trustees Of The University Of Pennsylvania Modified immune cells having enhanced function and methods for screening for same
AU2019269601A1 (en) 2018-05-17 2020-11-26 Regents Of The University Of Minnesota Drug-resistant immune cells and methods of use thereof
US12497611B2 (en) 2018-08-17 2025-12-16 Yale University Compositions and methods for high-throughput activation screening to boost T cell effector function
GB201813528D0 (en) 2018-08-20 2018-10-03 Ucl Business Plc Factor IX encoding nucleotides
US10842885B2 (en) 2018-08-20 2020-11-24 Ucl Business Ltd Factor IX encoding nucleotides
US20220170097A1 (en) 2018-10-29 2022-06-02 The Broad Institute, Inc. Car t cell transcriptional atlas
US12534714B2 (en) 2019-03-18 2026-01-27 The Broad Institute, Inc. Type VII CRISPR proteins and systems
CN120944827A (zh) 2019-03-27 2025-11-14 宾夕法尼亚大学董事会 Tn-MUC1嵌合抗原受体(CAR)T细胞疗法
JP7803014B2 (ja) 2019-09-30 2026-01-21 バイオベラティブ セラピューティクス インコーポレイテッド レンチウイルスベクター製剤
EP4048796B1 (de) 2019-10-23 2025-08-27 Yale University Zusammensetzungen und verfahren mit viralen vektorsystemen zur multiplexierten aktivierung endogener gene als immuntherapie und immun-gentherapie auf viraler basis
EP4114860A1 (de) 2020-03-06 2023-01-11 Go Therapeutics, Inc. Anti-glyco-cd44-antikörper und deren verwendungen
CN115916963A (zh) 2020-03-27 2023-04-04 门德斯有限公司 白血病来源的经修饰细胞用于增强过继性细胞治疗的效力的离体用途
US20210322471A1 (en) 2020-03-27 2021-10-21 Dcprime B.V. In vivo use of modified cells of leukemic origin for enhancing the efficacy of adoptive cell therapy
IL299333A (en) 2020-06-24 2023-02-01 Bioverativ Therapeutics Inc Methods for the purification of viral vectors
AU2021302958A1 (en) 2020-06-30 2023-02-16 Mendus B.V. Use of leukemia-derived cells in ovarian cancer vaccines
EP4210832A1 (de) 2020-09-14 2023-07-19 Vor Biopharma, Inc. Chimäre antigenrezeptoren zur behandlung von krebs
CA3196677A1 (en) 2020-11-05 2022-05-12 Erik Hans MANTING Use of tumor-independent antigens in immunotherapies
US12397055B2 (en) 2021-01-22 2025-08-26 Mendus B.V. Methods of tumor vaccination
US20250326855A1 (en) 2021-03-05 2025-10-23 Go Therapeutics, Inc. Anti-glyco-cd44 antibodies and their uses
WO2022190058A1 (en) 2021-03-12 2022-09-15 Dcprime B.V. Methods of vaccination and use of cd47 blockade
CA3228178A1 (en) 2021-08-05 2023-02-09 Go Therapeutics, Inc. Anti-glyco-muc4 antibodies and their uses
US20250066498A1 (en) 2021-09-03 2025-02-27 Go Therapeutics, Inc. Anti-glyco-lamp1 antibodies and their uses
WO2023034569A1 (en) 2021-09-03 2023-03-09 Go Therapeutics, Inc. Anti-glyco-cmet antibodies and their uses
US20240002800A1 (en) 2022-05-16 2024-01-04 Mendus B.V. Use of leukemia-derived cells for enhancing natural killer (nk) cell therapy
WO2024236547A1 (en) 2023-05-18 2024-11-21 Inceptor Bio, Llc Modified phagocytic cells expressing chimeric antigen receptors comprising a herpes virus entry mediator (hvem) co-stimulatory domain and uses thereof
WO2025046513A1 (en) 2023-08-29 2025-03-06 Inceptor Bio, Llc Methods of manufacturing myeloid-derived cells from hematopoietic stem cells and compositions and uses thereof
WO2026047626A1 (en) 2024-08-30 2026-03-05 Inceptor Bio, Llc Compositions and methods involving immune cells engineered for binding bispecific antibodies for use in cell therapy
CN119925619A (zh) * 2024-12-31 2025-05-06 首都医科大学 一种递送外源质粒dna的赋形剂及其制备和应用

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4543252A (en) * 1982-01-21 1985-09-24 The Regents Of The University Of California Cationic oligopeptides having microbicidal activity
JPS60501759A (ja) 1983-07-01 1985-10-17 バテル　メモリアル　インステイチユ−ト 生物分解性ポリペプチド及び薬剤の緩慢な放出のためのその使用
ATE60340T1 (de) 1984-10-19 1991-02-15 Battelle Memorial Institute Durch mikroorganismen abbaubares polypeptid und seine verwendung fuer die fortschreitende abgabe von medikamenten.
US5749847A (en) * 1988-01-21 1998-05-12 Massachusetts Institute Of Technology Delivery of nucleotides into organisms by electroporation
JP3368603B2 (ja) 1992-02-28 2003-01-20 オリンパス光学工業株式会社 遺伝子治療用処置具
US5439440A (en) 1993-04-01 1995-08-08 Genetronics, Inc. Electroporation system with voltage control feedback for clinical applications
AU6714094A (en) 1993-04-28 1994-11-21 Ribozyme Pharmaceuticals, Inc. Ocular delivery of nucleic acid
US5679647A (en) * 1993-08-26 1997-10-21 The Regents Of The University Of California Methods and devices for immunizing a host against tumor-associated antigens through administration of naked polynucleotides which encode tumor-associated antigenic peptides
FR2715847B1 (fr) 1994-02-08 1996-04-12 Rhone Poulenc Rorer Sa Composition contenant des acides nucléiques, préparation et utilisations.
AU710504B2 (en) 1994-03-15 1999-09-23 Brown University Research Foundation Polymeric gene delivery system
US6271205B1 (en) * 1994-09-21 2001-08-07 University Of Massachusetts Medical Center Cancer treatment by expression of differentiation factor receptor
US6040295A (en) * 1995-01-13 2000-03-21 Genemedicine, Inc. Formulated nucleic acid compositions and methods of administering the same for gene therapy
FR2732218B1 (fr) 1995-03-28 1997-08-01 Flamel Tech Sa Particules a base de polyaminoacide(s) et susceptibles d'etre utilisees comme vecteurs de principe(s) actif(s) et leurs procedes de preparation
GB9600272D0 (en) * 1996-01-06 1996-03-06 Univ Nottingham Polymers
US5704908A (en) 1996-10-10 1998-01-06 Genetronics, Inc. Electroporation and iontophoresis catheter with porous balloon
GB9623051D0 (en) 1996-11-06 1997-01-08 Schacht Etienne H Delivery of DNA to target cells in biological systems
US6048551A (en) 1997-03-27 2000-04-11 Hilfinger; John M. Microsphere encapsulation of gene transfer vectors
FR2766706B1 (fr) 1997-07-30 2001-05-25 Biovector Therapeutics Sa Complexes particulaires stables de charge globale neutre ou negative de structure multilamellaire composes par au moins une substance biologiquement active globalement anionique et un constituant cationique, leur preparation et utilisation
US6040925A (en) 1997-12-12 2000-03-21 Hewlett-Packard Company Radial and pruned radial interpolation
US6383811B2 (en) 1997-12-30 2002-05-07 Mirus Corporation Polyampholytes for delivering polyions to a cell
WO2000002621A1 (en) * 1998-07-13 2000-01-20 Genetronics, Inc. Skin and muscle-targeted gene therapy by pulsed electrical field
US7396919B1 (en) * 1998-07-17 2008-07-08 Mirus Bio Corporation Charge reversal of polyion complexes
US5945290A (en) * 1998-09-18 1999-08-31 Isis Pharmaceuticals, Inc. Antisense modulation of RhoA expression
FR2786098B1 (fr) * 1998-11-20 2003-05-30 Flamel Tech Sa Particules a base de polyaminoacide(s) et susceptibles d'etre utilisees comme vecteurs de principe(s) actif(s), suspension colloidale les comprenant et leurs procedes de fabrication
DK1189971T3 (da) 1999-06-17 2005-07-11 Univ Gent Funktionelle poly-alpha-aminosyrederivater der er egnede til modificering af biologisk aktive materialer, samt anvendelse deraf
WO2000078358A2 (en) 1999-06-18 2000-12-28 The Collaborative Group, Ltd. Hyaluronic acid microspheres for sustained gene transfer
WO2001013723A1 (en) 1999-08-20 2001-03-01 Mirus Corporation Charge reversal of polyion complexes
CA2401239A1 (en) * 2000-03-03 2001-09-13 Valentis, Inc. Improved poloxamer and poloxamine compositions for nucleic acid delivery
WO2002024899A2 (en) * 2000-09-25 2002-03-28 Valentis, Inc. Improved system for regulation of transgene expression

Also Published As

Publication number Publication date
EP1259265B1 (de) 2011-06-01
JP2003525912A (ja) 2003-09-02
WO2001066149A3 (en) 2002-03-14
US7491537B2 (en) 2009-02-17
US20070213287A1 (en) 2007-09-13
AU2001245427A1 (en) 2001-09-17
EP1259265A2 (de) 2002-11-27
BR0108962A (pt) 2002-12-24
US20030109478A1 (en) 2003-06-12
JP4987205B2 (ja) 2012-07-25
DK1259265T3 (da) 2011-07-11
WO2001066149A2 (en) 2001-09-13
CA2401327C (en) 2014-05-06
CA2401327A1 (en) 2001-09-13
US7173116B2 (en) 2007-02-06

Similar Documents

Publication Publication Date Title
ATE511400T1 (de) Nukleinsäure-fomulierungen zur genverabreichung
PT1404300E (pt) Composições farmacêuticas de dispersões de fármacos e polímeros neutros
ZA200206723B (en) Cosmetic compositions containing a methacrylic acid copolymer, a silicone and a cationic polymer, and uses thereof.
DE60142616D1 (de) Hydrogelzusammensetzung zur transdermalen arzneistoffabgabe
BR0210520A (pt) Composições farmacêuticas de dispersões de fármacos amorfos misturados com polìmeros
AU2002301098A1 (en) Cosmetic compositions containing a methacrylic acid copolymer, a silicone and a cationic polymer, and uses thereof
DE69909519D1 (de) Biologisch abbaubare ph/thermosensitive hydrogele zur verzörgerten freisetzung biologisch aktiver stoffe
BR0212475A (pt) Composições farmacêuticas
FR2829387B1 (fr) Compositions cosmetiques contenant un copolymere d'acide methacrylique, une dimethicone et un polymere cationique et leurs utilisations
GB0317999D0 (en) Improvements in or relating to drug delivery systems
AU2002300821A1 (en) Cosmetic compositions containing a methacrylic acid copolymer, a silicone and a cationic polymer, and uses thereof
DE69943084D1 (de) Mucoadhäsive zusammensetzung zur verabreichung von biologisch aktiven substanzen in tiergewebe
MY130332A (en) Pharmaceutical formulation comprising iota-carrageenan and at least one neutral gelling polymer
DE69940635D1 (de) Copolymer-zusammensetzungen zur oralen verabreichung
FR2819179B1 (fr) Compositions photoprotectrices a base de polymeres amphiphiles
AU2357202A (en) Ion-strength independent sustained release pharmaceutical formulation
DE60116359D1 (de) Kahalalid f formulierung
ZA200206724B (en) Cosmetic compositions containing a methacrylic acid copolymer, a dimethicone, a nacreous agent and a cationic polymer, and uses thereof.
FR2829384B1 (fr) Compositions cosmetiques contenant un copolymere d'acide methacrylique, une silicone et un polymere cationique et leurs utilisations
AU2002300696A1 (en) Cosmetic compositions containing a methacrylic acid copolymer, a dimethicone, a nacreous agent and a cationic polymer, and uses thereof
HN2003000115A (es) Formulacion farmaceutica que comprende melatonina
SE0001916D0 (sv) Novel formulation
DE60111503D1 (de) Pharmazeutische zusammensetzungen enthaltend terbinafin
DE60121925D1 (de) Arzneimittel zur verabreichung an schleimhäute
IT1318578B1 (it) Articolatore, particolarmente per le applicazioni in odontoiatria eodontotecnica.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties